New antibody aims to supercharge immune attack on tumors
NCT ID NCT07610941
First seen Jun 02, 2026 · Last updated Jun 15, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called MST-0312 in people with advanced solid tumors like lung, melanoma, bladder, colorectal, and triple-negative breast cancer. The drug is designed to activate a natural immune pathway to help the body fight cancer more effectively. It is given alone or with another cancer drug (pembrolizumab). The main goals are to check safety, how the drug moves through the body, and whether it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Universidad De Navarra
NOT_YET_RECRUITINGMadrid, 28027, Spain
-
Hospital Clinico Universitario De Valencia
NOT_YET_RECRUITINGValencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario 12 De Octubre
NOT_YET_RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario Hm Sanchinarro
RECRUITINGMadrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.